Vetoquinol offers equine patients faster healing for most lesions with patented light therapy system

FORT WORTH, TEXAS (Sept. 13, 2022) – Vetoquinol USA announces the Phovia dermatology system is now available to equine veterinarians. Phovia helps accelerate natural skin regeneration for most lesions so horses can heal quickly and completely.

Phovia can be used to help heal common equine dermatological conditions including:

• Surgical incisions
• Skin infections
• Traumatic wounds, and
• As a component of a summer sore treatment program

“Since January 2021, Phovia has been helping dogs and cats heal from a variety of skin conditions. Now, the system is proven in horses — bringing our equine friends a new tool for faster healing,” said Eric M. Alsup, DVM, Country Manager, Vetoquinol USA. “Quick and complete healing can help horses and their owners spend less time dealing with bandages and wound care.”

Phovia is a proven service that can be performed by trained veterinarians, technicians, or assistants. Plus, it requires no additional care from owners.

Light therapy, or photobiomodulation, has been shown to stimulate collagen and secretion of several growth factors including epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), and transforming growth factor beta (TGF-β).¹

Despite exerting a biological effect, the Phovia system is generally very safe for users and animals. Plus, it does not contain antibiotics, steroids, or immunomodulating drugs that may interfere with eligibility for competition.²^,³ 

For more information, visit phoviausa.com.

About Vetoquinol USA

Headquartered in Fort Worth, Texas, Vetoquinol USA is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production, and marketing of FDA, EPA, NASC, and AAFCO-regulated pharmaceutical, nutritional, and dermatological products for small and large animals.

For more information, visit vetoquinolusa.com.

References

1.  Marchegiani, A. et al. (2021) Current Applications and Future Perspectives of Fluorescence Light  Energy Biomodulation in Veterinary Medicine. Vet Sci, Jan 25;8(2):20.
2.  Marchegiani, A., et al. (2019), Fluorescence biomodulation in the management of canine interdigital pyoderma cases: a prospective, single‐blinded, randomized and controlled clinical study. Vet Dermatol, 30: 371-e109.
3.  Salvaggio, A., et al. (2020) Effect of the topical Klox fluorescence biomodulation system on the healing of canine surgical wounds. Veterinary Surgery, 49:719-727.

©2022 Vetoquinol USA, Inc. Phovia is a trademark of Vetoquinol S.A. It is manufactured by Klox Technologies and distributed by Vetoquinol USA under license from Klox Technologies.